This high dose at the start quickly fills up the bodys stores and starts fixing the deficiency
This requires either a caloric deficit or high activity levels that create energy demand
The most commonly reported events in active arms were mild and transient: injection site reactions in some subcutaneous subjects, occasional headache, and in some oral dosing arms, minor gastrointestinal tolerance issues
Frontiers in Bioengineering and Biotechnology, 9
Summary: AOD 9604 and retatrutide are both unlicensed investigational compounds in the UK, and there is no clinical evidence or regulatory guidance supporting their combined use
Others are sold as non-prescription compounded products, such as "GLP-3" or "GLP-RT" which is known as Retatrutide or "GLP-2" or "GLP-TZ" which is known as Tirzepatide, from research-use peptide suppliers